Aura Biosciences (AURA) Other Accumulated Expenses (2020 - 2026)

Aura Biosciences has reported Other Accumulated Expenses for 7 years, with the latest figure at $7.5 million in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses rose 124.62% year-over-year to $7.5 million; the trailing twelve-month figure through Mar 2026 stood at $7.5 million (up 124.62% YoY), and the FY2025 full-year result was $242000.0, up 28.72% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $7.5 million, up from $242000.0 in the prior quarter.
• The five-year high for Other Accumulated Expenses was $7.5 million in Q1 2026, with the low at $152000.0 in Q3 2025.
• Historically, Other Accumulated Expenses has averaged $1.3 million across 5 years, with a median of $766000.0 in 2023.
• Annual changes were most pronounced in 2024 — Other Accumulated Expenses soared 434.97% — and 2025, when it tumbled 85.66%.
• Aura Biosciences' Other Accumulated Expenses stood at $325000.0 in 2022, then surged by 187.69% to $935000.0 in 2023, then slumped by 79.89% to $188000.0 in 2024, then advanced by 28.72% to $242000.0 in 2025, then jumped by 3014.05% to $7.5 million in 2026.
• The last three Other Accumulated Expenses figures came in at $7.5 million (Q1 2026), $242000.0 (Q4 2025), and $152000.0 (Q3 2025), per Business Quant data.